Sarepta Therapeutics Shares Surge 34% on Restructuring Plan, 20 Stocks Moving Premarket

Sarepta Therapeutics shares surged 34.1% in pre-market trading after the company announced a strategic restructuring plan to focus on high-value, high-impact programs and support long-term financials. Other stocks moving in pre-market trading include 22nd Century Group, Volcon, Windtree Therapeutics, and Monarch Casino & Resort. Losers include reAlpha Tech Corp, LQR House Inc, NioCorp Developments Ltd, Nuwellis, Soluna Holdings, Global Interactive Technologies, Pitanium Limited, and Jade Biosciences.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares surge by 34.1% in pre-market trading on July 2, 2025, following the company's announcement of a strategic restructuring plan. The plan aims to focus on high-value, high-impact programs and support long-term financial viability. Other notable stocks moving in pre-market trading include 22nd Century Group, Volcon, Windtree Therapeutics, and Monarch Casino & Resort, while reAlpha Tech Corp, LQR House Inc, NioCorp Developments Ltd, Nuwellis, Soluna Holdings, Global Interactive Technologies, Pitanium Limited, and Jade Biosciences were among the losers.

The restructuring plan, announced on July 16, 2025, includes a strategic review of Sarepta's pipeline to prioritize potentially best-in-class siRNA platform assets. The company expects to achieve approximately $400 million in annual cost savings through a 36% workforce reduction of approximately 500 employees and pipeline reprioritization. This restructuring is part of Sarepta's effort to maintain long-term, sustainable growth and meet its 2027 financial obligations.

The company also provided an update on the ELEVIDYS label, its first and only approved gene therapy for the treatment of Duchenne muscular dystrophy. The U.S. FDA has requested and Sarepta has agreed to include a black box warning for acute liver injury (ALI) and acute liver failure (ALF) in the ELEVIDYS label. Sarepta is also exploring additional prophylactic immunosuppression for non-ambulant patients, with plans to submit a protocol to the FDA imminently.

Sarepta's preliminary second quarter 2025 financial results showed total net product revenue of $513 million, with ELEVIDYS net product revenue of $282 million and RNA-based PMOs net product revenue of $231 million. The company reported combined research and development expense and selling, general and administrative expense of $294 million on a non-GAAP basis.

The restructuring plan is expected to enhance Sarepta's financial flexibility and meet its 2027 financial obligations. The company aims to maintain access to its $600 million revolving credit facility and generate robust cash flow to proactively manage liabilities, including the repayment of the 2027 convertible note.

Sarepta will host an investor call on July 16, 2025, at 4:30 p.m. Eastern time to discuss these updates. The event will be webcast live under the investor relations section of Sarepta's website.

References:
[1] https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-strategic-restructuring-and